New York, NY
Dr. David H. Ilson
1275 York Avenue
New York, NY 10021
University of Connecticut
New York University School of Medicine - 1986
New York University Medical Center Bellevue Hospital
Memorial Sloan-Kettering Cancer Center
Dr. David H. Ilson is a respected medical oncologist who specializes in treating patients that have upper gastrointestinal cancers, specifically esophageal cancer. After completing an undergraduate degree at the University of Connecticut he attended a combined M.D. and Ph.D. program at New York University School of Medicine. Dr. Ilson earned a Masters Degree and Ph.D. in Basic Sciences along with his medical degree. His internship and residency in Internal Medicine was completed at New York University Medical Center Bellevue Hospital followed by a Fellowship at Memorial Sloan-Kettering Cancer Center. In 1992 Dr. Ilson joined the Gastrointestinal Oncology Service at Memorial Sloan-Kettering Cancer Center.
Clinical Research and Affiliations
Dr. Ilson's research focuses on studying new ways to treat advanced disease by using combined modality therapy to treat locally advanced diseases. Modality therapy is used to treat tumors with a combination of chemotherapy, radiation and surgery. He is a member of the Cancer and Leukemia Group B and the Radiation Therapy Oncology Group. He is active in the Upper Gastrointestinal Cancer Guidelines Committee of National Comprehensive Cancer Network and the Intergroup Esophageal and Gastric Cancer Task Force Committee.
He currently is an Associate Attending Physician and Associate Member of Memorial Sloan-Kettering Cancer Center in New York City. Dr. Ilson also works as an Associate Professor of Medicine at Weill Medical College at Cornell University. He has experience in the treatment of malignant mesothelioma as well as the treatment of other cancers including colorectal, esophageal, pancreatic, gastric and other gastrointestinal cancers and unknown primary tumors.
Dr. Ilson has authored and co-authored a number of scholarly articles including, "Prognostic factors after combined modality treatment of squamous cell carcinoma of the esophagus," published in the Journal of Thoracic Oncology. He also co-authored, "Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience," in the Annals of Oncology and "Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime?" in the Journal of Clinical Oncology.
Memorial Sloan-Kettering Cancer Center Physician Profile